News & Updates
Filter by Specialty:
Polycythemia ups risk of MACE, VTE in men on testosterone therapy
Men receiving testosterone therapy (TT) who develop polycythemia are at greater risk for major adverse cardiovascular events (MACE) and venous thromboembolism (VTE) in the first year of therapy, according to a recent study.
Polycythemia ups risk of MACE, VTE in men on testosterone therapy
06 Jun 2022Early ivermectin use does not confer benefit for COVID-19
In outpatients with an early diagnosis of COVID-19 at high risk for serious illness, treatment with the antiparasitic ivermectin did not reduce the incidence of hospital admission due to disease progression or of prolonged emergency department observation, findings from the TOGETHER trial suggest.
Early ivermectin use does not confer benefit for COVID-19
06 Jun 2022Very low HBsAg levels predict HBsAg loss, disease remission after therapy cessation
Following discontinuation of nucleot(s)ide analogue therapy, only about one-third of patients with HBeAg-negative chronic hepatitis B (CHB) achieve disease remission, with rare HBsAg loss, as reported in a study. The likelihood of HBsAg loss and disease remission is high in the presence of very low HBsAg levels at baseline.
Very low HBsAg levels predict HBsAg loss, disease remission after therapy cessation
04 Jun 2022Step-down therapy may be the better strategy for certain COPD patients
Switching from triple therapy to dual bronchodilation improves symptom control in patients with chronic obstructive pulmonary disease (COPD) in a new analysis of the DACCORD study.
Step-down therapy may be the better strategy for certain COPD patients
03 Jun 2022HRT use tied to reduced COVID-19 death risk
The use of hormonal replacement therapy (HRT) among postmenopausal women may be associated with a reduced risk of mortality after a COVID-19 diagnosis, according to a retrospective study from Sweden.
HRT use tied to reduced COVID-19 death risk
02 Jun 2022Novel biomarkers predict immunotherapy response, side effects in HCC
A team of Singapore-based researchers has identified two blood biomarkers that not only predict clinical response to immune checkpoint inhibitors (ICIs) in hepatocellular carcinoma (HCC) patients but also the incidence of side effects from the same treatment.
Novel biomarkers predict immunotherapy response, side effects in HCC
02 Jun 2022Multivitamins help improve colorectal cancer survival
Patients who take multivitamin supplements at a moderate dose following their diagnosis of nonmetastatic colorectal cancer (CRC) appear to have a lower mortality, reports a recent study.